导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.92% | 2151/4773 |
| 近一周 | -1.35% | 1067/5458 |
| 近一月 | -2.13% | 1392/5421 |
| 近一季 | -5.60% | 2875/5205 |
| 近半年 | -3.01% | 2256/4920 |
| 近一年 | 5.39% | 1691/4361 |
| 近两年 | 61.90% | 1190/2954 |
| 近三年 | 43.08% | 665/2253 |
| 成立以来 | 109.49% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.01% 1659/4961 |
10.24% 2429/5312 |
- - |
- - |
| 2025 | 26.51% 1625/4813 |
2.35% 1400/3635 |
5.91% 524/4076 |
13.47% 2990/4524 |
2.86% 824/4813 |
| 2024 | 21.02% 428/3463 |
2.31% 797/2808 |
0.72% 553/3014 |
15.28% 1765/3129 |
1.88% 1009/3463 |
| 2023 | -9.34% 1152/2656 |
2.98% 1283/2280 |
-2.66% 628/2385 |
-3.34% 899/2515 |
-6.43% 1773/2655 |
| 2022 | -21.03% 1007/2207 |
-14.72% 987/1919 |
6.28% 733/2016 |
-13.40% 897/2113 |
0.61% 1479/2208 |
| 2021 | -2.33% 847/1822 |
-2.83% 716/1255 |
5.57% 801/1330 |
-4.49% 711/1466 |
-0.30% 1219/1822 |
| 2020 | 50.30% 169/1250 |
-6.76% 507/1028 |
17.28% 378/1067 |
17.15% 114/1164 |
17.32% 132/1184 |
| 2019 | 43.82% 186/1092 |
26.69% 385/739 |
1.59% 118/788 |
1.50% 393/850 |
10.09% 163/918 |
| 2018 | -19.28% 158/834 |
- - |
-7.39% 160/631 |
-0.01% 166/660 |
-11.80% 353/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 安信量化精选沪深300增强A VS. 长安沪深300非周期A(740101) |